en Advanced Sciences and Technologies in Public Health Advanced Sciences and Technologies in Public Health پژوهشي Research Article <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Background & Aims</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">Corona virus disease-19 (COVID-19) is an evolving global disease which has burst into 2019. SARS-CoV-2 infects human cells through recognition of and binding to angiotensin converting enzyme-2 (ACE2) through the spike (S) glycoprotein. Spike is an immunogenic protein that can elicit immune responses. Multi-epitope vaccines are novel and efficient class of vaccines which are designed by linking the B and T cells. These epitopes stimulate both humoral and cellular immunity. </span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Materials & Methods</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> Based on bioinformatics online tools, appropriate epitopes of S protein were selected, linked together via suitable linkers, a TLR4 binding adjuvant was added, and a multi-epitope construct was constructed. The 3D model of the construct was predicted, refined, and validated. The antigenicity, allergenicity, solubility, and physico-chemical properties of vaccine were checked. The B cell conformational epitopes and IFN-&gamma; inducing parts were detected. The adjuvant and TLR4 binding were evaluated by docking and protein-protein complex stability was assessed by elastic-mode analysis. The coding sequence of the vaccine construct was optimized and sub-cloned in expression vector through an <i>in silico</i> approach. Finally, the structure, energy, and stability of vaccine coding mRNA were evaluated. </span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Results</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> Ten continuous B cell epitopes, 9 T helper epitopes, and 8 CTL epitopes were chosen. The results showed that multi-epitope vaccine is a stable and soluble protein which can stimulate humoral and cellular immunity. Besides, the vaccine could stimulate immunity without inducing allergenicity in human body. </span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Conclusion</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">Finally, the vaccine can bind the TLR4 appropriately and can be expressed by a recombinant vector. The designed multi-epitope vaccine against COVID-19 could be considered as a suitable candidate for experimental studies.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt"></span></span></span></span><br> &nbsp; Bioinformatics, COVID-19, SARS-CoV-2, Spike glycoprotein, Vaccine 180 204 http://hsm.umsu.ac.ir/browse.php?a_code=A-10-83-2&slc_lang=en&sid=1 Mehdi Tourani medical.biotechnology2@yahoo.com 10031947532846001721 10031947532846001721 Yes Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Sadra Samavarchi Tehrani medical.biotechnology3@yahoo.com 10031947532846001722 10031947532846001722 No Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Ahmad Movahedpour ahmad.movahed14@gmail.com 10031947532846001723 10031947532846001723 No Behbahan Faculty of Medical Sciences, Behbahan, Iran Sahar Rezaei Arablouydareh saharrezaei1475504@gmail.com 10031947532846001724 10031947532846001724 No Reproductive Health Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran (First Corresponding Author) Amir Maleksabet maleksabet.amir@yahoo.com 10031947532846001725 10031947532846001725 No Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran Amir Savardashtaki medical.biotechnology4@yahoo.com 10031947532846001726 10031947532846001726 No Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran Hojat Ghasemnejad‐Berenji h_ghasem_nejad@yahoo.com 10031947532846001727 10031947532846001727 No Reproductive Health Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran (First Corresponding Author) Mortaza Taheri-Anganeh mortazataheri@yahoo.com 10031947532846001728 10031947532846001728 No Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran (Second Corresponding Author)